OBJECTIVES::  To estimate and evaluate the budget impact of using DUAL [Daclatasvir (DCV) + Asunaprevir (ASV)] in the treatment of patients with Hepatitis C (HCV) in the Peruvian Social Health Insurance (EsSalud). METHODS::  from a Markov model (MONARCH), the natural history of HCV and its complications is projected, verifying the incremental financial impact of DUAL against Telaprevir (TVR) or Simeprevir (SMV), both + peginterferon-alpha and ribavirin (A/R) in eleven scenarios for EsSalud. A 5 year period was considered and a cohort of 1,000 HCV patients each year was assumed. Values are expressed in Nuevos Soles, 2016. Costs are those associated with antiviral treatment, treatment of adverse events and health states. RESULTS::  In the first year, when DUAL was compared with SMV+A/R in naïve patients and in pre-treated patients who relapsed, a saving of S/.428.514 and S/.20.708.296 was observed respectively in nine out of eleven scenarios. The most important savings are presented in the first year (due to the difference in treatment costs), but remain, at a lower level, for 5 years (due to the higher cure rate with DUAL). The only exception is when DUAL was compared with A/R, where no savings were observed due to its extremely low cost; however A/R is is not considered the SoC in Perú. CONCLUSIONS::  The incorporation of DUAL in EsSalud results in important savings from the first year.